Guavinoside B
Guavinoside B is an orally active α-glucosidase inhibitor with an IC50 of 0.21 mM. Guavinoside B upregulates the expressions of Nrf2, GCLC and NQO1 induced by Acetaminophen (HY-66005), downregulates the expression of p-JNK, and reduces intracellular ROS levels. Guavinoside B decreases serum TNF-α levels induced by Acetaminophen, alleviates hepatocellular infiltration and necrosis, and improves liver-related biochemical parameters. Guavinoside B is applicable to the research of diabetes and Acetaminophen-induced liver injury.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 372955-18-5
- Formule: C28H28O13
- Masse moléculaire:572.51
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
α‑glucosidase 0.21 mM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
10 μg/mL
Compound: Compound 9
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 25862199] |
Guavinoside B potently inhibits purified α-glucosidase enzyme activity with an IC50 of 0.21 mM[1].
Guavinoside B (3.3-100 μM; 24 h) does not affect the viability of HepG2 cells, either with or without 5 mM Acetaminophen (HY-66005) treatment[2].
Guavinoside B (3.3-30 μM; 16 h) reduces Acetaminophen-induced intracellular ROS accumulation by 28.6% in HepG2 cells, with weaker, non-significant effects at 3.3 and 10 μM[2].
Guavinoside B (10-30 μM; 16 h) upregulates Nrf2 and GCLC mRNA expression in untreated HepG2 cells, and (3.3-30 μM; 16 h) upregulates Nrf2, GCLC, and NQO1 mRNA expression in Acetaminophen-treated HepG2 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 (human hepatocellular carcinoma cells)
-
Concentration:3.3, 10, 30 μM (alone; co-treated with 5 mM Acetaminophen)
-
Incubation Time:16 h
-
Result:Increased mRNA expression levels of Nrf2 and GCLC at 10 and 30 μM when used alone.
Showed no impact on NQO1 mRNA expression when used alone.
Increased mRNA expression levels of Nrf2, GCLC, and NQO1 at 3.3, 10, and 30 μM when used with Acetaminophen.
-
Cell Line:HepG2 (human hepatocellular carcinoma cells)
-
Concentration:3.3, 10, 30 μM (alone; co-treated with 5 mM Acetaminophen)
-
Incubation Time:16 h
-
Result:Increased protein expression levels of Nrf2, GCLC, and NQO1 at 3.3, 10, and 30 μM when used alone.
Increased protein expression levels of Nrf2, GCLC, and NQO1 at 3.3, 10, and 30 μM when used with Acetaminophen compared to the Acetaminophen-only group.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 7 weeks old) injected with Acetaminophen[2]
-
Dosage:100 mg/kg/d
-
Administration:p.o.; daily; 7 consecutive days
-
Result:Markedly alleviated Acetaminophen-induced hepatic pathological changes, including reduced hepatocyte necrosis and inflammation around central venous lesions.
Significantly reduced serum AST and ALT levels.
Significantly reduced hepatic ROS and MDA levels, and reversed Acetaminophen-induced depletion of hepatic GSH and SOD.
Significantly increased hepatic mRNA expression of SOD1 and GPx1.
Significantly up-regulated hepatic mRNA and protein expression levels of Nrf2, GCLC, and NQO1.
Significantly reduced serum TNF-α levels from 35.3 pg/mL (Acetaminophen-only group) to 27.3 pg/mL, and significantly inhibited Acetaminophen-induced JNK phosphorylation in liver tissue.
Chemical Information
-
CAS No. 372955-18-5
-
Masse moléculaire 572.51
-
Formule C28H28O13
-
SMILES
O=C(C1=CC=CC=C1)C2=C(C(C)=C(C(C)=C2O)O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)COC(C4=CC(O)=C(C(O)=C4)O)=O)O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Xu L, et al. Inhibitory activity and mechanism of guavinoside B from guava fruits against α-glucosidase: Insights by spectroscopy and molecular docking analyses. J Food Biochem. 2022;46(7):e14101. [Content Brief]
[2]. Li Y, et al. Guavinoside B from Psidium guajava alleviates acetaminophen-induced liver injury via regulating the Nrf2 and JNK signaling pathways. Food Funct. 2020 Sep 23;11(9):8297-8308. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Guavinoside B Related Classifications
HY-N17855 Related Classifications
Powered by Bioz